OXY
34
-8
GIS
35
-12
PHM
46
2
IBM
51
-2
TRIP
64
4
KLAC
56
11
DVN
24
2
RL
75
2
SJM
19
2
BMY
38
-3
JNJ
35
5
SYY
41
-2
MO
44
-3
AMAT
41
6
KSS
38
2
FFIV
63
2
CLX
62
-3
NWS
75
4
NOV
47
2
PSA
45
2
OXY
34
-8
GIS
35
-12
PHM
46
2
IBM
51
-2
TRIP
64
4
KLAC
56
11
DVN
24
2
RL
75
2
SJM
19
2
BMY
38
-3
JNJ
35
5
SYY
41
-2
MO
44
-3
AMAT
41
6
KSS
38
2
FFIV
63
2
CLX
62
-3
NWS
75
4
NOV
47
2
PSA
45
2
Financhill
Back

Kymera Therapeutics 10K Form

Sell
39

KYMR
Kymera Therapeutics

Last Price:
$40.79
Seasonality Move:
2.79%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KYMR News And Ratings

See the #1 stock for the next 7 days that we like better than KYMR

KYMR Financial Statistics

Sales & Book Value

Annual Sales: $78.6M
Cash Flow: $-50M
Price / Cash Flow: 0
Annual Sales: $13.79
Price / Book: 2.96

Profitability

EPS (TTM): -2.34000
Net Income (TTM): $-167.5M
Gross Margin: --
Return on Equity: -27.19%
Return on Assets: -21.71%

Kymera Therapeutics Earnings Forecast

Key Kymera Therapeutics Financial Ratios

  • The Research & Development expenses have been 240.59% of Revenue.
  • The Interest Expense is -0.13% of Operating Income.
  • The Net Earning history of KYMR is -186.99% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

Kymera Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: KYMR
Website: kymeratx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 8.55
Quick Ratio: 8.29

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KYMR Technical Analysis vs Fundamental Analysis

Sell
39
Kymera Therapeutics (KYMR) is a Sell

Is Kymera Therapeutics a Buy or a Sell?